Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug

Vir Biotechnology, a San Francisco-based firm focused on infectious disease, and GlaxoSmithKline, the British drug giant, said Monday that they are beginning a study of an antibody drug aimed at treating Covid-19.